ReviewImmunologic research2026
"IL-40: A novel immunoregulatory axis at the crossroads of inflammation, tissue remodeling, and cancer immunity".
Review in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-40 (IL-40), encoded by the C17orf99 gene, is a recently identified B cell-associated cytokine that bridges innate and adaptive immune responses. Since its discovery in 2017, IL-40 has emerged as a pleiotropic immunoregulatory factor with broad implications in human diseases. Elevated IL-40 levels are consistently reported across systemic and organ-specific autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, and autoimmune thyroid diseases. In these conditions, IL-40 correlates with disease activity, inflammatory burden, and adverse outcomes. Mechanistically, beyond B-cell differentiation and IgA production, IL-40 induces neutrophil extracellular trap (NET) formation (NETosis), triggering extracellular release of peptidylarginine deiminase 4. PAD4 catalyzes citrullination of intracellular proteins, converting arginine to citrulline residues, generating neoepitopes that break immune tolerance and drive anti-citrullinated protein antibody (ACPA) production-a hallmark of rheumatoid arthritis and related autoimmunities. Beyond autoimmunity, dysregulated IL-40 is observed in viral infections (COVID-19, Epstein-Barr virus), sepsis, and pneumonia, suggesting roles in host defense, systemic inflammation, and immunopathology. IL-40 deficiency impairs IgA homeostasis and alters gut microbiota, implicating it in mucosal immunity and microbiome crosstalk. In oncology, aberrant IL-40 expression is reported in solid tumors (breast cancer, hepatocellular carcinoma) and hematologic malignancies (acute/chronic myeloid leukemias, Hodgkin lymphoma), indicating context-dependent functions in tumor biology. Elevated IL-40 in obesity, metabolic syndrome, type 2 diabetes, and allergic diseases further implicates this cytokine in low-grade chronic inflammation and hypersensitivity. Overall, IL-40 represents a promising immunoregulatory cytokine with diagnostic and therapeutic potential across immune-mediated diseases and cancer. However, current evidence remains largely observational and animal-based, while mechanistic and clinical investigations are scarce. Future research should prioritize identifying IL-40 receptor(s) and downstream signaling pathways through well-designed cellular and molecular studies, alongside large-scale multicenter trials, to fully elucidate its biological functions and clinical utility.
Indexed as
Identifiers
42631903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.